Clinical trials in follicular lymphoma

The table below shows a list of The Lymphoma Group's current clinical trials open for recruitment for follicular lymphoma patients.

To find out how you can access one of these clinical trials or to contact us with a question, see our page 'How to be referred'.

For an explanation on the different phases of trials click here.

 

 

Trial Name

 

Description

 

Click for more information (external page)

 

ADCT-402-101

 

A Phase 1 study evaluating the new drug ADCT-402.

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

BI 1206 CRUK CD32b

 

Phase 1/2a study looking at blocking the CD32b protein with the antibody BI 1206.

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

GILEAD 1757

 

Phase 1b study of the selective BTK inhibitor ONO/GS-4059.

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

LYMRIT-37-01

 

Phase 1-2 study of the antibody Betalutin® which targets the CD37 antigen

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

MEDI4736 (FUSION)

 

Phase 1-2 study to assess the safety and tolerability of durvalumab, the anti-pd-l1 antibody.

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

ReBel

 

Phase 1-2 trial of lenalidomide and rituximab +/- bendamustine

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

*Please note, we update this page fortnightly

With special thanks to the following:

;